Although COVID vaccinations have fallen short of goals, Pfizer announced in late 2021 that they expect COVID-19 vaccine sales to reach $65 billion or more through the end of the 2022 fiscal year. That figure represents an expected $29 billion in 2022, which is higher than what analysts expected from the efforts.
The American-based drugmaker created its COVID shot with the help of German partner BioNTech SE.
Pfizer says it’s looking to keep making deals for the vaccine with other countries, which could drive sales much higher than expected. The company announced that it expects to make up to four billion doses.
The sales figures are based on the revenues for 1.7 billion doses being sold.
How Are the Other Vaccines Faring in Sales?
Moderna reached the market after Pfizer with its COVID vaccine. Although sales have been strong for it, the drugmaker struggled to ramp up production as much as its competitor. Sales in 2021 were revised to be as low as $15 billion, which is about half of what Pfizer was able to achieve.
During the first nine months of 2021, Johnson and Johnson earned just $766 million in revenues from its vaccine. The company announced that it expects several contracts to be fulfilled during the fiscal year’s fourth quarter, which should boost total sales to about $2.5 billion.
AstraZeneca is started to profit from its sales of the COVID vaccine they developed for distribution. The company earned about three times as much as J&J in 2021, with total sales expected to reach $9.74 billion across all its product lines. Vaccine sales reached nearly $2.2 billion.
If you haven’t gotten your shot yet, experts recommend that you should as more variants emerge. You can also potentially boost immune system strength with Host Defense.